Silence
Silence Therapeutics Selects Dose, Regimen for Registrational Phase III Trial of Lp(a) siRNA Drug
The investigational cardiovascular drug, zerlasiran, reduced lipoprotein(a) levels by 90 percent or greater in a Phase II trial, the company said.
If Novartis and others show that lowering Lp(a) improves cardiovascular outcomes, it may spur a new class of drugs that change treatment and testing paradigms.